key: cord-0714923-9tuht6eu authors: Rezaee, Haleh; Pourkarim, Fariba; Pourtaghi‐Anvarian, Samira; Entezari‐Maleki, Taher; Asvadi‐Kermani, Touraj; Nouri‐Vaskeh, Masoud title: Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview date: 2021-01-09 journal: Pharmacol Res Perspect DOI: 10.1002/prp2.705 sha: 7d001d4cdee23aaad87ea2bc9a903f564b24df56 doc_id: 714923 cord_uid: 9tuht6eu Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID‐19 in order to minimize the adverse reactions. and patients with underlying disease (i.e., cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancer). 11 The effective pharmacotherapy can reduce the mortality and morbidity of COVID-19. 12 Studies are recommended various combination therapy with chloroquine, lopinavir/ritonavir (Kaletra), ribavirin (RBV) and tocilizumab (TCZ) for the treatment of COVID-19. [13] [14] [15] [16] On May 2, 2020, FDA approves emergency use of remdesivir (RDV) for COVID-19. One of the most important problems in pharmacotherapy is drug-drug interaction (DDI) which may significantly increase the adverse effects of drug. The present article focuses on reviewing DDIs of chloroquine, RBV, Kaletra, TCZ, and RDV to reduce side effects of COVID-19 treatment. Ribavirin (Virazole ® ), as a broad-spectrum antiviral drug, was approved by FDA in 1986 and administered as an aerosol for infants with respiratory syncytial virus infection. 17 RBV is a nucleos(t)ide analogue polymerase inhibitor which is used for the treatment of hepatitis C virus infection in combination with sofosbuvir and pegylated interferon alpha-2b. 18, 19 The t 1/2 , t max , and bioavailability after a single oral dose of RBV (400 mg) is 1.5 h, 100 h, and 45%-65%, respectively. 20, 21 Combination therapy with RBV and Xiyanping injection (the extraction of Andrographis paniculata) is widely used for inflammation and bronchitis in china. 22 Also, it used for viral hemorrhagic fever as off-label. 23, 24 RBV is teratogenic and contraindicated in pregnancy (Category X). Also, it is necessary avoiding pregnancy during and 6 months after RBV therapy. 25 Dose adjustment is required in patients with renal and liver impairment. The absorption of RBV occurs in the proximal small intestine by Na + -dependent nucleoside (N1) transporters. 26 It is not bound to plasma proteins. The commonly reported adverse effects of RBV were dyspnea (5%), headache (41%-69%), fatigue (25%-58%), anxiety (47%), apnea, hypotension, rash (15%-17%), and conjunctivitis (5%). An interaction between RBV and warfarin was reported in a 61-year-old man under treatment with interferon, RBV, and warfarin. 27 Also, Peterson et al. 28 RBV may increase the hepatotoxicity of lamivudine 29 and zidovudine may enhance the risk of hematological toxic effects of RBV, specially, and anemia. [29] [30] [31] The mechanism of interaction between RBV and zidovudine is competitive inhibition of intracellular phosphorylation of zidovudine by RBV. 32 The interaction between RBV and abacavir can be associated with competitive inhibition in metabolic pathways, 33 but this interaction is not significant. 34 Mitochondrial toxicity and severe metabolic acidosis syndrome are life-threatening adverse reactions associated with concomitant use of RBV and didanosine that can manifest with symptoms, including pancreatitis, hepatic steatosis, and lactic acidosis. [35] [36] [37] [38] Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in metabolism of azathioprine (AZA) which RBV inhibit this enzyme and enhance the risk of myelotoxicity (i.e., anemia, thrombocytopenia) of AZA. 39 Interaction between RBV and telaprevir was described by Gutierrez-Valencia et al. 40, 41 which may enhance the risk of hematological toxicity by increasing the blood levels of RBV. The mechanism of action of this interaction is inhibition of the proximal tubule transport of RBV by telaprevir. The significant drug interaction may occur between alpha and beta antagonists with sofosbuvir/RBV regimen during HCV therapy that close monitoring is required. 42 The study conducted by Ramanathan et al. 43 has not demonstrated a pharmacokinetic interaction between tenofovir and RBV. The details of RBV drug interactions are shown in Table 1 . Chloroquine, a 4-aminoquinolone derivative, is used in the prophylaxis and treatment of uncomplicated malaria. It is also effective in systemic lupus erythematosus and rheumatoid arthritis. [44] [45] [46] The serious side effects associated with chloroquine are retinopathy, ototoxicity, and myopathy. [47] [48] [49] [50] Chloroquine can inhibit organic anion transporting polypeptide 1A2 that the inhibition of this transporter is associated with retinopathy. 51 Chloroquine can induce psoriasis in patient as exfoliative erythroderma and pustular psoriasis. 52 The National Health Commission of the People's Republic of China for tentative treatment of COVID-19 (version 6) recommends chloroquine for the treatment of COVID-19 at doses of 500 mg oral twice daily for 10 days that may shorten the recovery period and improve pulmonary complication findings in imaging. 53 In patients with CrCl <10 ml/min, the recommended dose of chloroquine is 50% normal dose. 16, 53, 54 Chloroquine is completely absorbed after oral administration and it is distributed widely in tissues that include kidney, liver, lung and spleen. 54 About 60% of chloroquine is bound to plasma proteins. It is metabolized by CYP2C8 and CYP3A4 enzymes in the liver and converted into active metabolites (desethylchloroquine and bisdesethylchloroquine). 54, 55 The mechanism of action of chloroquine is inhibition of the polymerization of heme which heme accumulate as toxic agent in the parasite. 54 The concomitant administration of chloroquine and paracetamol can increase significantly C max of paracetamol and should be used cautiously. 56 The absorption of chloroquine may decrease by antacids and their administration should be separated by at least 4 h to reduce the risk of drug interaction. 57,58 A controlled study was performed by Ette et al. 59 for analysis of interaction between cimetidine and chloroquine. The results showed that cimetidine may decrease the metabolism of chloroquine and increase its volume of distribution. The study conducted by Ette et al. 60 showed no significant pharmacokinetic interaction between ranitidine and chloroquine. Therefore, ranitidine is the H 2 blocker of choice for ulcer patients receiving chloroquine. Several clinical studies indicate that chloroquine may increase the metformin-induced cell apoptosis and significantly enhance the metformin-induced inhibition of cancer cell proliferation. [61] [62] [63] Chloroquine may increase the risk of hypoglycemic effect of antidiabetic agents. 64 Chloroquine may reduce the plasma concentration of methotrexate by 20%, 65 but there is no significant pharmacokinetic interaction between chloroquine and methotrexate. Pukrittayakamee et al. 66 studied the potential interaction between primaquine and chloroquine in 16 healthy volunteers. Based on the results, chloroquine may increase the serum concentration of primaquine and enhance the risk of QT prolongation. Chloroquine may increase the mean plasma concentration of penicillamine by 34%. 67 Chloroquine may reduce the plasma concentration of levothyroxine by increasing the catabolism and worsen the control of hypothyroidism. 68 Chloroquine may reduce the bioavailability and serum concentration of praziquantel by 50 may decrease by non-competitive inhibition of its metabolism by chloroquine. 69 Acute dystonic reaction was reported in a 30-year-old woman under treatment with chloroquine and metronidazole. 70 The pharmacokinetic study do not exhibit drug interaction between chloroquine and azithromycin. 71 Chloroquine may reduce the therapeutic effect of agalsidase Alfa and Beta. 72 Chloroquine may reduce the bioavailability of ampicillin by decreasing the rate of gastric emptying and enhancement of bowel motility. 73 The co-administration of chloroquine and cyclosporine for malaria prophylaxis or rheumatoid arthritis may elevate cyclosporine levels. [74] [75] [76] Ciprofloxacin is a fluoroquinolone antibiotic with broad antibacterial activity which concomitant use of it with chloroquine may decrease its plasma concentration to below the minimum inhibitory concentration. 77 Abbreviations: AZA, azathioprine; IMPDH, inosine monophosphate dehydrogenase; RBV, ribavirin. the risk of retinopathy. 79 The interaction between chloroquine and other QT prolonging agents such as antipsychotic drugs, cisapride, dronedarone, fluoxetine, tricyclic antidepressants, citalopram, escitalopram, amiodarone, mefloquine and beta blocker (sotalol) has been life threatening, leading to QT prolongation and ventricular arrhythmias. [80] [81] [82] Chloroquine can antagonize the antiepileptic effect of carbamazepine. 81 Chloroquine may inhibit the metabolism of metoprolol by the inhibition of CYP2D6. 83 An interaction between chloroquine and methylene blue was reported by Rengelshausen and co-workers. 84 No pharmacokinetic interaction is observed between chloroquine and imipramine. 85 There is no pharmacokinetic interaction between chloroquine with sulfadoxine and pyrimethamine. 86 Activated charcoal can reduce plasma level of chloroquine by 99% after 5 min. 87 Interaction between indinavir and chloroquine can be enhanced the antimalarial effect of chloroquine against chloroquine-resistant line and chloroquine-sensitive line P. chabaudi. 88 There is no clinically significant interaction between tafenoquine and chloroquine. 89 The details of chloroquine drug interactions are summarized in Table 2 . Kaletra ® approved in 2000 for widely used in combination with other antiretroviral compounds to treat HIV-1 in children 14 days of age and older, also in adults. 90 Lopinavir binds to the HIV-protease site of activity and prevents the formation of functional proteins required for viral pathogenesis, resulting in non-infectious and immature viruses. 91 Ritonavir inhibits lopinavir metabolism via CYP3A4 and boosts the plasma levels of lopinavir. Furthermore, when co-formulated with ritonavir that improves the bioavailability of lopinavir. So it can be said, the significant antiretroviral effects of Kaletra are due to lopinavir. 92 Kaletra binds to plasma proteins approximately 98%-99%, and elimination half-life after a single-dose administration is nearly 2-3 h. Kaletra is mainly eliminated with feces and is <2% in the urine. 90, 93 Kaletra is classified as category C in pregnancy and only prescribed when the beneficial impacts of this on the fetus exceed from harmful effects. 90 The possible adverse effects of Kaletra are hyperglycemia (≤5%), abdominal pain (1%-11%), pancreatitis (≤2%), diarrhea (7%-28%), lipid elevation (3%-39%), nausea (5%-16%), and vomiting (adults 2%-7%; children 21%), and QT pro- Thus, Kaletra will be many interactions with other groups of medications, and it is crucial to consider these interactions in pharmacotherapy. These interactions with details were described in Table 3 . Tocilizumab (Actemra ® ) is a recombinant humanized monoclonal antibody against the soluble and membrane receptors of IL-6. It mainly used to treatment of autoimmune diseases such as rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. 117 The mechanism of action of TCZ is inhibition of IL-6 receptors, which stimulates regulatory B cells, and reduces the expression of inflammatory cytokines and chemokine genes. As a result, it increases the expression of synovial fluid proteins. 118 Elimination of TCZ depends on the serum concentration of the drug and is associated with the degree of IL-6 receptor saturation. The non-linear pathway is promi- 118, 124 Studies show that IL-6 is one of the key inflammatory cytokines in the development of SARS-induced inflammation, which raises the insufficiency of alveolar blood-gas exchange and eventually leads to lung fibrosis and organ failure. 125, 126 In a study performed on 21 patients with critical TA B L E 2 "QT-prolonging antidepressants such as citalopram, escitalopram, fluoxetine" is in a same group with other "OT-prolonging agent" The effect of chloroquine on ADME of other agent Interacting drugs The effect of kaletra on ADME of other agent The effect of other agent on ADME of kaletra Consequence Atorvastatin is a CYP3A4 substrate and kaletra will increase the concentration by 5 The effect of kaletra on ADME of other agent The effect of other agent on ADME of kaletra Consequence Table 4 . The effect of kaletra on ADME of other agent The effect of other agent on ADME of kaletra Consequence 132 No interaction found between immunosuppressants and RDV. Nevertheless, when using with RDV concomitantly monitoring levels of immunosuppressive medications suggested. 133 RDV at in vitro studies appears to be a substrate for CYP2C8, CYP2D6, and CYP3A4 enzymes. However, on in vivo conditions, the metabolism of RDV is following the action of hydrolase, which indicates that potential clinical interactions with inhibitors or inducers of CYP enzymes are unlikely. For example, the concurrent use of RDV with carbamazepine could decrease the levels of RDV significantly, whereas this interaction not reported experimentally. Moreover, according to the weak role of hepatic enzymes in RDV metabolism, the probability of this interaction will be much lower. In general, RDV drug interactions are not verified carefully. Accordingly, possible interactions may help to discover potential clinical drug interactions associated with RDV. 134 Generally, the evidence about the safety and efficacy of RDV in the treatment of COVID-19 is limited. Due to the ambiguous effects of RDV against COVID-19, it has not been obtained definitive approval from FDA. Only ordered for patients in clinical trials, emergency states, or compassionate use. 135, 140, 141 These interactions with details were described in Table 4 . Drug interactions of each drug are described in details and tabulated for easy access. It will be useful to guide clinicians in drug selection, improve safety of treatment, and decrease the risk of adverse drug events. The authors declare that there is no conflict of interest. Not applicable. Masoud Nouri-Vaskeh https://orcid.org/0000-0002-6656-0292 Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A novel coronavirus outbreak of global health concern Clinical characteristics of fatal cases of COVID-19 in Tabriz, Iran: an analysis of 111 patients World Health Organization. World Health Organization: coronavirus disease (COVID-19) Situation dashboard Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia Fecal transmission in COVID-19: a potential shedding route Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Dyspneic and non-dyspneic (silent) hypoxemia in COVID-19: possible neurological mechanism The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China Angiotensin 1-7: a novel strategy in COVID-19 treatment Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures Discovering drugs to treat coronavirus disease 2019 (COVID-19) Molecular mechanisms of action of ribavirin update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection Peginterferon and ribavirin for chronic hepatitis C The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: a prospective, randomized, controlled trial Hemorrhagic fever viruses as biological weapons: medical and public health management Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever Australian recommendations for the management of hepatitis C virus infection: a consensus statement Intestinal absorption of ribavirin is preferentially mediated by the Na + -nucleoside purine (N1) transporter Inhibition of warfarin activity by ribavirin Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons Drug interactions with zidovudine phosphorylation in vitro Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy Mitochondrial toxic effects and ribavirin Nucleoside analogues and mitochondrial toxicity Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy Telaprevir: pharmacokinetics and drug interactions Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems Antimalarial agents: chloroquine, hydroxychloroquine, and quinacrine The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review Chloroquine retinopathy: a report of eight cases with ERG and dark-adaptation findings The ototoxicity of chloroquine phosphate Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2 Paper presented at: Annales de Dermatologie et de Venereologie 8334a 8326d d94d3 29df3 51d7d a8aef c2/files/ b218c feb1b c5463 9af22 7f922 bf6b8 17.pdf. Accessed February Goodman and Gilman Manual of Pharmacology and Therapeutics, 2. Philadelphia: McGraw Hill Professional Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes The effect of chloroquine on paracetamol disposition and kinetics The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine Adsorption of paracetamol and chloroquine phosphate by some antacids Chloroquine elimination in humans: effect of low-dose cimetidine Effect of ranitidine on chloroquine disposition Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions Autophagy as a modulator and target in prostate cancer Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis Pharmacokinetic interactions between primaquine and chloroquine Pharmacokinetic interactions of penicillamine in rheumatoid arthritis Interaction of thyroxine sodium with antimalarial drugs The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans Chloroquine-induced acute dystonic reactions in the presence of metronidazole Lack of a pharmacokinetic interaction between azithromycin and chloroquine Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents Reduced ampicillin bioavailability following oral coadministration with chloroquine Interaction between cyclosporin and chloroquine Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine Drug interaction of chloroquine with ciclosporin Effect of chloroquine on the urinary excretion of ciprofloxacin Effect of chloroquine on the bioavailability of ciprofloxacin in man Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine Clinically significant drug interaction profiles of chloroquine analogues with adverse consequences and risk management Drug interactions with antimalarial medications in older travelers: a clinical guide Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria Lack of pharmacokinetic interaction between chloroquine and imipramine Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda Prevention of chloroquine absorption by activated charcoal Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects Lopinavir/ritonavir in the treatment of HIV-1 infection: a review HIV-protease inhibitors Enhanced boosting of oral absorption of lopinavir through electrospray coencapsulation with ritonavir The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019 Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial Role of Lopinavir/Ritonavir in the treatment of Covid-19: a review of current evidence, guideline recommendations, and perspectives A review of drugdrug interactions in older HIV-infected patients A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications Drugdrug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients? Pharmacokinetic interactions between quinine and lopinavir/ritonavir in healthy Thai adults Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs Interactions between antifungal and antiretroviral agents Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/ lopinavir in a patient with atrial fibrillation Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir Ritonavir and efavirenz significantly alter the metabolism of erlotinib-an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer Use of antineoplastic agents in patients with cancer who have HIV/AIDS Hum Vaccines Immunother Tocilizumab: a review in rheumatoid arthritis Tocilizumab: the first interleukin-6-receptor inhibitor Tocilizumab in the treatment of rheumatoid arthritis and beyond Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data Extraordinary GUrich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response Aberrant pathogenic GM-CSF + T cells and inflammatory CD 14+ CD 16+ monocytes in severe pulmonary syndrome patients of a new coronavirus Effective treatment of severe COVID-19 patients with tocilizumab RoActemra 20 mg/mL concentrate for solution for infusion. EU summary of product characteristics Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance Safety profile of biological therapies for treating rheumatoid arthritis Remdesivir as a Potential Therapy Against COVID-19 Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions Safety and Drug-Drug Interaction Considerations for Double Concentrated 2% Propofol Remdesivir: a review of its discovery and development leading to human clinical trials for treatment of COVID-19 COVID-19 The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses How should we treat pregnant women infected with SARS-CoV-2? BJOG Compassionate use of remdesivir for patients with severe Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview